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Abstract
Angelman syndrome (AS), a genetic disorder occurring in approximately one in every 15,000 births, is characterized by
severe mental retardation, seizures, difficulty speaking and ataxia. The gene responsible for AS was discovered to be UBE3A
and encodes for E6-AP, an ubiquitin ligase. A unique feature of this gene is that it undergoes maternal imprinting in a
neuron-specific manner. In the majority of AS cases, there is a mutation or deletion in the maternally inherited UBE3A gene,
although other cases are the result of uniparental disomy or mismethylation of the maternal gene. While most human
disorders characterized by severe mental retardation involve abnormalities in brain structure, no gross anatomical changes
are associated with AS. However, we have determined that abnormal calcium/calmodulin-dependent protein kinase II
(CaMKII) regulation is seen in the maternal UBE3A deletion AS mouse model and is responsible for the major phenotypes.
Specifically, there is an increased aCaMKII phosphorylation at the autophosphorylation sites Thr
286 and Thr
305/306, resulting
in an overall decrease in CaMKII activity. CaMKII is not produced until after birth, indicating that the deficits associated with
AS are not the result of developmental abnormalities. The present studies are focused on exploring the potential to rescue
the learning and memory deficits in the adult AS mouse model through the use of an adeno-associated virus (AAV) vector to
increase neuronal UBE3A expression. These studies show that increasing the levels of E6-AP in the brain using an exogenous
vector can improve the cognitive deficits associated with AS. Specifically, the associative learning deficit was ameliorated in
the treated AS mice compared to the control AS mice, indicating that therapeutic intervention may be possible in older AS
patients.
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Introduction
Angelman syndrome is a genetic disorder resulting in severe
mental retardation, ataxic gait, lack of speech, seizures that may be
difficult to control, and frequent laughter [1]. The gene
responsible for AS is UBE3A and it is unique in that it is one of
a small family of human imprinted genes. UBE3A undergoes
maternal imprinting in the brain; thus, the paternal copy is
silenced and the only active copy inherited is maternal. AS can
occur from a variety of genetic abnormalities of the 15q11–q13
chromosome, each of which render the UBE3A gene silenced. The
majority of AS cases (70%) occur through a de novo deletion
(,4 Mb) of 15q11–q13 of the maternal chromosome which
incorporates the UBE3A gene [2], but it can also occur as a result
of abnormal methylation of the maternal copy, preventing its
expression [3,4] or uniparental disomy in which two copies of the
paternal gene are inherited [5,6]. The remaining AS cases arise
through various UBE3A mutations of the maternal chromosome or
they are diagnosed without a genetic cause (12–15%). Current
estimates indicate that AS is present in about one in every 15,000
births [7], though the actual number of diagnosed AS cases is
lower likely due to misdiagnosis. UBE3A codes for the E6-
associated protein (E6-AP) ubiquitin ligase. E6-AP is an E3
ubiquitin ligase, therefore it exhibits specificity for its protein
targets, which include the tumor suppressor molecule p53 [8], a
human homologue to the yeast DNA repair protein Rad23 [9],
E6-AP itself, and Arc, the most recently identified target [10,11].
The anatomy of the mouse and human AS brain shows no major
alterations compared to the normal brain, indicating the cognitive
deficits may be biochemical in nature as opposed to developmental
[12,13].
The AS mouse model used in this study, which contains a
disruption of the maternal UBE3A gene through a null mutation of
exon 2, was developed by Jiang et al. (1998). This model has been
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recapitulating the major phenotypes characteristic of AS patients.
For example, the AS mouse has inducible seizures, poor motor
coordination, hippocampal-dependent learning deficits, and
defects in hippocampal LTP. We previously found that the
cognitive deficits in the AS mouse model are associated with
abnormalities in the phosphorylation state of calcium/calmodulin-
dependent protein kinase II (CaMKII) [14]. There was a
significant increase in phosphorylation at both the activating
Thr
286 site as well as the inhibitory Thr
305 site of aCaMKII
without any changes in total enzyme level, resulting in an overall
decrease in its activity. There was also a reduction in the total
amount of CaMKII at the postsynaptic density, indicating a
reduction in the amount of active CaMKII. With this identifica-
tion, a mutant mouse model was developed with a point mutation
at the Thr
305 site preventing phosphorylation. When this mutant
CaMKII mouse model was crossed with the AS mouse, the
phenotype of the AS mouse was rescued. Seizure activity, motor
coordination, hippocampal-dependent learning, and LTP were
restored similar to wildtype levels. These studies were the first to
identify a particular defect in AS associated with the resulting AS
phenotype. The preponderance of aCaMKII is expressed
postnatally in the mammalian brain suggesting that the major
phenotypes of the AS mouse model are due to postnatal
biochemical alterations as opposed to a global developmental
defect [15]. However, because this study utilized a mutation in
CaMKII, the possibility that improvements were due to
developmental rescue could not be formally excluded.
In this study, we sought to determine if the major hippocampal-
dependent cognitive defects could be rescued in the adult mouse
through a UBE3A gene replacement strategy in the hippocampus
using recombinant adeno-associated virus (rAAV) serotype 9,
which has been shown to have one of the highest transgene
expressions in the brain compared to other serotypes. The vector
used in this study is a type 2 terminal repeat (TR2)-flanked UBE3A
gene, and the control vector is a TR2-flanked green fluorescent
protein (GFP). We found that by using an exogenous UBE3A gene
administered directly into the hippocampus, there was a significant
improvement in associative learning. This is the first study
demonstrating cognitive rescue in adult AS mice and indicates
that therapeutic intervention in AS patients may be efficacious
even into adulthood.
Results
As previously mentioned, one of the targets of E6-AP is itself.
This is hypothesized to be a mechanism to regulate levels of
maternally expressed protein; however, we were concerned that
transfected neurons would express significantly more E6-AP
protein than normally observed from WT maternal gene
expression. Quantitative assessment of neuronal E6-AP was
determined by immunohistochemistry 8 weeks following trans-
duction (Fig. 1A). Quantified immunoreactivity of E6-AP
determined for the entire hippocampal formation revealed equal
amounts of E6-AP expression in AS TR2-UBE3A mice compared
to wild type (WT) age matched controls and barely detectable in
AS TR2-GFP mice (Fig. 1B ANOVA Tukey [F(2,154)=9.422,
P,0.0001]). These results show that AS TR2-UBE3A mice do not
overexpress E6-AP protein and have levels comparable to wild
type mice.
A severe deficit in LTP induction is well established in the AS
mouse model [12]. We measured LTP in area CA1 from
hippocampal slices of AS TR2-UBE3A and AS TR2-GFP mice
and compared this to WT responses. LTP was induced using a
theta-burst stimulation (TBS) protocol as this high frequency
stimulation (hfs) protocol reveals the greatest difference in LTP
induction between AS and WT mice [14]. Consistent with
previous reports, AS TR2-GFP mice showed a severe LTP deficit
compared with WT mice (Fig. 2A); however, the post-tetanic
potentiation (PTP) and early phase of LTP in AS TR2-UBE3A
mice was equivalent to WT (Fig. 2B ANOVA Tukey
[F(2,44)=6.017, P,0.05]). There was no significant difference
seen between any of the groups during late phase LTP, which
compared the last 5 minutes of fEPSPs slopes (Fig. 2B ANOVA
Tukey [F(2,43)=2.865, P.0.05]). There was a slow decline in
potentiation ,30 minutes post-stimulation. This level was main-
tained throughout the experiment to 60 minutes, suggesting that
UBE3A expression can partially rescue the LTP defect in the AS
mouse model using a non-saturating hfs. There was no change in
presynaptic function determined by pre-pulse facilitation (PPF)
(Fig. 2C) and the rescue in early phase LTP induction was not the
result of enhanced PTP (Fig. 2D).
The AS mouse model exhibits significant defects in motor
coordination [12,16,17]. A single injection of rAAV in the
hippocampus did not significantly increase UBE3A expression in
the cerebellum (data not shown), and we found that rotorod
Figure 1. E6-AP protein levels were restored to wildtype levels in the TR2-UBE3A treated AS mice. (A) Representative coronal slices
through the hippocampus from each group stained for E6-AP. (B) Quantitative analysis of the IHC revealed a significant increase in E6-AP expression
in the WT and AS-TR2-UBE3A mice compared to the AS TR2-GFP group, while there was no significant change between the WT and AS TR2-UBE3A
mice. Results shown represent the mean with standard error.
doi:10.1371/journal.pone.0027221.g001
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to AS TR2-GFP controls (Fig. 3A). To ensure that the motor
coordination defect in the AS TR2-UBE3A mice was not the
result of altered activity or anxiety, an open field (Fig. 3B ANOVA
Tukey [F(2,27)=0.07563, P.0.05)]) and elevated plus maze test
(Fig. 3C ANOVA Tukey [F(2,27)=0.5290, P.0.05] and Fig. 3D
ANOVA Tukey [F(2,27)=2.472, P.0.05]) were performed and
showed no changes in AS TR2-UBE3A versus AS TR2-GFP
mice.
Associative fear conditioned learning is disrupted in the AS
mouse model [12,16]. Contextual fear conditioned learning was
assessed through freezing behavior to the context 24 hours after
training. Although there was no change between any of the groups
during the training phase of fear conditioning (Fig. 4A), our AS
TR2-UBE3A mice show associative learning comparable to that of
WT mice (Fig. 4B ANOVA Tukey [F(2,55)=71.65, P,0.0001])
when placed back in the same context 24 hours after training.
There were no significant differences seen in the cued test between
any of the groups 24 hours after training (data not shown).
Another form of learning shown to be disrupted in the AS
mouse model is spatial learning evaluated using the Morris water
maze task. All groups were trained for 5 days to find the hidden
platform and recorded latencies find that AS TR2-UBE3A have
significantly lower latency compared to AS TR2-GFP mice on
training days 3 and 4 (Fig. 5B). A probe trial given 24 hours after 5
days of training showed a significant difference in the number of
target platform crossings compared to opposite platform crossings
in all three groups (Fig. 5B). There was also no significant
difference in the time spent in the target quadrant between groups
(Fig. 5D) suggesting equivalent normal spatial memory formation
for all groups. However, when tested 72 hours after the last day of
training (day 5), the WT and AS TR2-UBE3A mice had
significantly more target platform crossings compared to opposite
platform crossings (Fig. 5C). Despite the increase in platform
crossings seen with the TR2-UBE3A mice, this is not associated
with a spatial bias to the target quadrant (Figure 5D,E). Neither
the TR2-UBE3A nor AS TR2-GFP showed a significant increase
for the target quadrant above chance (25%) or compared to WT
mice. Thus, AS TR2-UBE3A mice retained a search strategy for
the target platform without a significant spatial bias to the target
quadrant. The difference observed between AS TR2-GFP and AS
TR2-UBE3A mice is not a result of increased activity, greater
swim speed or decreased anxiety.
Discussion
Recent clinical trials for disorders categorized as developmental,
such as Fragile X mental retardation and Rett syndrome, are
showing promising results for cognitive disruption and associated
behavioral symptoms [18,19,20,21,22]. Angelman syndrome has
Figure 2. Increasing E6-AP in the AS mouse results in improvements in early phase LTP. (A) AS TR2-GFP mice have significant deficits in
hippocampal synaptic plasticity. LTP was induced following 20 min of baseline recordings. (B) Immediately following TBS, acute hippocampal slices
taken from AS TR2-GFP mice had significant deficits in the average PTP (average of first 5 min recordings of fEPSPs slopes). To compare late phase
LTP, the last 5 min recordings of fEPSPs slopes were averaged, and there was no significant difference between any of the groups. (C) There were no
significant differences between any of the groups in either PPF or (D) PTP, indicating that short term synaptic plasticity mechanisms are unaffected.
Results shown represent the mean with standard error.
doi:10.1371/journal.pone.0027221.g002
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in either AS group. (B) Total distance travelled during the open field test revealed no significant difference between any of the treatment groups. (C)
Time spent in the open arms of the elevated plus maze was used to determine general anxiety. (D) Time spent immobile in the elevated plus maze
was not significantly different in any of the groups. Results shown represent the mean with standard error.
doi:10.1371/journal.pone.0027221.g003
Figure 4. AS mice receiving TR2-UBE3A had significant improvements in associative learning. (A) There were no differences during the
training phase of fear conditioning, indicating that all groups of mice were capable of freezing to the same extent. (B) AS TR2-GFP mice show
significant deficits in contextual fear conditioning when assessed 24 h after training. AS TR2-UBE3A mice, however, froze at the same rate as the
wildtype mice. Results shown represent the mean with standard error.
doi:10.1371/journal.pone.0027221.g004
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[23,24,25]. We previously showed a genetic rescue of the major
phenotypes in the AS mouse model using a specific mutation to
alpha CaMKII [16]. Temporal regulation of alpha CaMKII
expression results in little expression prior to post natal day 5
followed by increased expression to maximal levels by post natal
day 21 [26]. The lack of appreciable CaMKII expression during
development of the central nervous system suggested that
CaMKII’s effect was altering synaptic function resulting in the
phenotype rescue. The present study sought to determine if
replacement of E6-AP protein in the hippocampal formation was
sufficient to recover the memory and synaptic plasticity defects
associated with hippocampus dysfunction in the adult AS mouse
model.
The use of the AAV-9 serotype particle allowed for a
preponderance of neurons within the hippocampus and entorhinal
cortex to show E6-AP protein accumulation. While the LTP defect
was not completely recovered, we were able to show a recovery of
the associative learning and memory defect when compared to
controls. Memory was also affected in the AS TR2-UBE3A mice
seen as an increase in non-spatial biased platform crossing
72 hours following training. These results suggest that the increase
in hippocampal LTP is associated with the amelioration of defects
in the Morris water maze and associative learning and memory.
Figure 5. AS TR2-UBE3A mice had significant improvements in the Morris water maze. (A) Escape latency to reach the platform during 5
days of training in Morris water maze. The only significant differences seen were an increase in latency for the AS TR2-GFP mice on day 3 and a
decrease in latency for wildtype mice on day 4 compared to the other two groups (2-way ANOVA Bonferroni: Interaction [F(8,100)=1.01, P.0.05];
Treatment [F(2,100)=5.30, P,0.05]; Time [F(4,100)=53.49, P,0.0001]; Matching [F(25,100)=5.37, P,0.0001]). The target platform is indicated by the
black circles. (B) Quantification of the number of platform crossings in the target (T), opposite (O), right (R), and left (L) quadrants during the probe
trial of the Morris water maze 24 hours after training indicate no significant differences among any of the groups in comparing target platform
crossings to opposite platform crossings (ANOVA Tukey WT: [F(3,35)=9.546, P,0.0005]; AS TR2-GFP: [F(3,35)=3.186, P,0.01]; AS TR2-UBE3A:
[F(3,39)=2.814, P,0.05]). All three groups learned the platform location based on a spatial bias as indicated by the time spent in the target quadrants
(Fig. 5D 24 h ANOVA Tukey [F(2,26)=1.027, P.0.05]) (C) A probe test 72 hours after training indicate that the WT and AS TR2-UBE3A groups had
significantly more target platform crossings compared to the number of opposite platform crossings (ANOVA Tukey WT: [F(3,35)=6.086, P,0.005]; AS
TR2-GFP: [F(3,35)=0.5650, P.0.05]; AS TR2-UBE3A: [F(3,39)=2.679, P,0.05]), but this improvement was not spatially biased as seen by the time spent
in the target quadrant (Fig. 5D 72 h ANOVA Tukey [F(2,25)=5.067, P,0.02]). Results shown represent the mean with standard error.
doi:10.1371/journal.pone.0027221.g005
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This defect has been considered to reside in the cerebellum, where
we found no detectable E6-AP production. However, these results
provide the first evidence that the cognitive disruption associated
with Angelman syndrome is not a developmental defect and can
be reversed in the adult AS mouse model. Moreover, these data
support the possibility of developing a beneficial therapeutic to
treat the cognitive and motor defects seen in adult human
Angelman syndrome.
Materials and Methods
Ethics Statement
All animal testing procedures were approved by the Institutional
Animal Care and Use Committee of the University of South
Florida and followed the NIH guidelines for the care and use of
laboratory animals (Approval ID number A4100-01).
Vector Construction
The UBE3A plasmid M43 clone (NCBI database U82122) was a
gift from Yong-Hui Jiang. UBE3A was sub-cloned into the
pTR12.1-MCS vector (which contains the short hybrid CMV
chicken beta-actin promoter as described in Mah et al. [27] at the
Spe I and Cla I cloning sites and sequenced. Virus was generated by
cotransfection of the UBE3A plasmid with the helper plasmids
pXX6 and pAAV9 in HEK293 cells (ATCC, Manassas, VA). The
resultingrecombinant virus waspurified usingan iodixanolgradient
as previously described [28]. A dot-blot assay was used to determine
the viral titer and is expressed as vector genomes (vg)/ml.
Breeding of animals
Mice with the UBE3A null mutation (AS) were described
previously [12]. All experiments were performed on mice that
have been backcrossed to the 129/SvEv line (Jackson Labs, Bar
Harbor, ME) at least 5 generations. Female mice containing the
null mutation were bred with 129/SvEv (WT) males to produce
maternally-deficient AS offspring and WT littermate controls.
Animals were kept on a 12 hour light/dark cycle and food and
water provided ad libitum. All animal testing procedures were
approved by the Institutional Animal Care and Use Committee of
the University of South Florida and followed the NIH guidelines
for the care and use of laboratory animals.
Intrahippocampal AAV Injections in AS Mice
Mice are anesthetized with isoflurane and placed in the
stereotaxic apparatus (51725D Digital Just for Mice Stereotaxic
Instrument, Stoelting, Wood Dale, IL). An incision is made
sagitally over the middle of the cranium and the surrounding skin
is pushed back to enlarge the opening. The following coordinates
are used to locate the left and right hippocampus: AP 22.7 mm,
L62.7 mm, and V 23.0 mm. Mice received bilateral intrahippo-
campal injections of either TR2-UBE3A particles at a concentra-
tion of 1.5610
12 genomes/mL (N=10) or TR2-GFP particles at a
concentration of 1.4610
12 genomes/mL (N=9) using a 10 mL
Hamilton syringe. Recombinant viral vectors in 1 mL volume were
co-administered with 1 mL of 20% mannitol in each hemisphere.
The wound is cleaned with saline and then closed using Vetbond
(NC9286393 Fisher Scientific, Pittsburgh, PA). Mice recovered in
a clean, empty cage on a warm heating pad and were then singly
housed until sacrificed.
General Activity and Anxiety
For all subsequent behavior testing, the following number of
animals were used for each group: 9 WT, 9 AS TR2-GFP, 10 AS
TR2-UBE3A. Activity was measured by the open field test. Mice
were placed in a 40640 cm acrylic chamber under normal
lighting conditions and allowed to explore for 15 min. Video
tracking software monitored movement, immobility, and distance
traveled (ANY-Maze, Stoelting, Wood Dale, IL). Anxiety was
measured by the elevated plus maze (EPM). The EPM consisted of
two well-lit open arms (35 cm) and two enclosed arms (35 cm)
facing each other. Each arm was attached to a common center
platform (4.5 cm) and the entire device was elevated 40 cm off the
ground. Each mouse was placed in the center platform and
allowed to explore for 5 min. Immobility was measured after the
mouse remained motionless for a minimum of 2 consecutive sec.
Motor coordination
The accelerating rotorod was used to assess motor coordination
and motor learning (Ugo Basile, Italy). Mice were placed on a
3 cm diameter rod with an initial rotation of 4 rpm and
accelerated to 40 rpm over a maximum of 5 min. Mice were
tested for latency to fall off the rod for 4 trials over 2 consecutive
days.
Associative fear conditioning
Fear conditioning was used to assess hippocampus function and
memory formation. Mice were placed in a 25625 cm sound-
attenuation chamber with a wire grid floor. Mice were allowed to
explore the context for 2 min before they received the conditioned
stimulus (CS, 90 db tone) for 30 sec. At the end of the 30 sec, mice
received a mild foot shock (0.5 mA: unconditioned stimulus (US)).
After 1.5 min, the mice received a second CS/US pairing and
monitoring continued for 2.5 min. Freezing was assessed by the
use of a weight transducer system (Panlab, Spain). Mice were
considered freezing if movement ceased for at least 2 consecutive
sec. 24 hrs following CS/US presentation, mice were placed back
into the chamber and allowed to explore for 3 min.
Spatial memory
The Morris Water maze test was used to determine spatial
memory formation. A 1.2 m diameter pool was filled with white
opaque water. A 10 cm diameter white platform was submerged
just below the water surface and large extra-maze cues positioned
around the room. Mice were placed in the pool and allowed to
swim to the escape platform for a maximum of 60 sec. Mice were
given 4 trials per day for 5 days. Latency to escape and swim speed
was measured by video tracking software (ANY-Maze, Stoelting,
Illinois). 24 and 72 hours following the 5
th day of training, the
platform was removed and swim patterns were monitored for
60 sec.
Hippocampal slice preparation and extracellular
recording
One hemisphere of each brain was used for electrophysiology
and the remaining hemisphere was preserved for histology. Slice
preparations and the theta-burst stimulation LTP protocol used
were previously described by Weeber et al. [29]. Briefly, the theta
burst stimulation consists of five trains of four pulses at 100 Hz
with an interburst interval (IBI) of 20 seconds.
Histology
Each hemisphere that was not used for electrophysiology was
immersion fixed in 4% PFA. Prior to sectioning with the cryostat,
tissue was transferred to 30% sucrose overnight. Endogenous
peroxidases were quenched with 0.3% hydrogen peroxide for
30 min before the blocking solution (2% BSA, 5% goat serum,
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then incubated overnight with antibody solution (2% BSA, 0.25%
Triton-X) with E6AP (A300-352A Bethyl Laboratories, Inc.) at
1:300. After washing with PBS, secondary antibody (Goat Anti-
Rabbit IgG(H+L) SouthernBiotech) was applied for one hour at
room temperature. Immunoreactivity was detected using a metal-
enhanced DAB substrate kit (Pierce). A Mirax Micro digital slide
scanner (Carl Zeiss USA) was used to photograph IHC sections
and MIRAX SCAN software was used to quantify E6-AP
expression in the hippocampus. Expression levels were normalized
to the wildtype.
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